Kiniksa Pharmaceuticals International plc discovers, acquires, and develops novel therapeutics primarily for cardiovascular and autoimmune indications. The company's commercial portfolio is anchored by ARCALYST (rilonacept), an FDA-approved biologic used to treat recurrent pericarditis and cryopyrin-associated periodic syndromes (CAPS). Beyond its marketed product, Kiniksa is advancing a clinical pipeline of investigational monoclonal antibodies, including KPL-387 and KPL-1161, which target IL-1 signaling pathways. The company also develops abiprubart and mavrilimumab for various immune-mediated diseases. Originally founded in 2015, the company focuses on rare and severe inflammatory conditions.
